Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Dec 10, 2021
- Accession no.
- 0001209191-21-068959
- Filed
- Dec 10, 2021
- Trade date
- Dec 6-9, 2021
- Filing delay
- 4 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $10.5K. It was filed 4 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +1,500 | $1.49 | +$2,235 | 11,091,706 | Direct | |
| Dec 7, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +1,900 | $1.55 | +$2,945 | 11,093,606 | Direct | |
| Dec 8, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +1,200 | $1.58 | +$1,896 | 11,094,806 | Direct | |
| Dec 9, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +2,000 | $1.69 | +$3,380 | 11,096,806 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.